[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-vertex-pharmaceuticals-why-a-815-target-makes-its-current-price-look-undervalued-FR":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":266,"suggestedPosts":344},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},95679,"Vertex Pharmaceuticals a réalisé un chiffre d'affaires de 12 milliards de dollars l'an dernier : Les analystes prévoient un prix de l'action de 815 $.","2026-03-04T14:00:00","2026-03-04T04:47:46","\u003Cp>Vertex a enregistré un chiffre d'affaires de 12 milliards de dollars en 2025 et a prévu 13,1 milliards de dollars en 2026, mais le chiffre le plus important arrivera au premier semestre, lorsque les résultats de l'essai pivot de Pove sur l'IgAN débloqueront ou réinitialiseront une franchise qui, selon les analystes, pourrait rivaliser entièrement avec la FK.\u003C\u002Fp>\n","\n\u003Ch3 class=\"wp-block-heading\" id=\"h-key-stats-for-vertex-pharmaceuticals-stock\">Chiffres clés de l'action Vertex Pharmaceuticals\u003C\u002Fh3>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>\u003Cstrong>Performance de la semaine dernière : \u003C\u002Fstrong>+4%\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Fourchette de 52 semaines : \u003C\u002Fstrong> 362,5 $ à 619,7\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>Cours actuel : \u003C\u002Fstrong> 474,3\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>La plupart des investisseurs ne savent jamais si une action est réellement sous-évaluée ou surévaluée. Les outils d'évaluation de TIKR, de qualité professionnelle, vous donnent une réponse claire et étayée par des données sur plus de 60 000 actions, et ce, gratuitement.\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-happened\">\u003Cstrong>Que s'est-il passé ?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>L'action Vertex Pharmaceuticals\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=36235&tid=2662297&ref=tikrblog\">(VRTX\u003C\u002Fa>) se négocie à 474,27 $ après un recul de 2,4 %, mais 77 000 patients atteints de fibrose kystique sous traitement et 12,3 milliards de dollars en liquidités indiquent que l'entreprise est en avance sur le cours de son action.\u003C\u002Fp>\n\n\n\n\u003Cp>Plusieurs dirigeants de Vertex, dont le vice-président exécutif et directeur commercial Duncan McKechnie et le directeur juridique Jonathan Biller, ont cédé des actions ordinaires entre le 18 février et le 2 mars, alors que l'action se situe 8,8 % en dessous de son plus haut niveau sur 52 semaines (519,68 $).\u003C\u002Fp>\n\n\n\n\u003Cp>Vertex a affiché un chiffre d'affaires de 12 milliards de dollars pour l'année 2025, a augmenté les bénéfices du quatrième trimestre de 24% en glissement annuel à 1,3 milliard de dollars et a prévu un chiffre d'affaires de 12,95 milliards de dollars à 13,1 milliards de dollars pour 2026, les produits hors FC visant à eux seuls 500 millions de dollars ou plus.\u003C\u002Fp>\n\n\n\n\u003Cp>Entre-temps, l'analyse intermédiaire de l'étude RAINIER, confirmée pour le premier semestre 2026, a eu un poids supplémentaire après que Reshma Kewalramani, PDG, a déclaré lors de l'appel à résultats du quatrième trimestre que \"pove est administré une fois par mois sous forme de dose sous-cutanée de petit volume délivrée par un auto-injecteur\", un profil que les néphrologues ont déjà signalé comme étant leur format d'administration préféré dans 74 engagements de payeurs couvrant 210 millions de vies.\u003C\u002Fp>\n\n\n\n\u003Cp>Avec les brevets TRIKAFTA intacts jusqu'en 2037, ALYFTREK protégé au-delà, et quatre verticales commerciales convergeant avec cinq programmes en phase pivot, Vertex entre dans une fenêtre de plusieurs années où les reins seuls, ancrés par des brevets sur l'IgAN, la néphropathie membraneuse et la myasthénie grave, pourraient rivaliser avec l'ampleur de sa franchise FK.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Découvrez le moment exact où Wall Street revalorise un titre avant que le reste du marché ne le fasse - suivez les changements de notation des analystes en temps réel avec TIKR, et ce gratuitement →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-wall-street-s-take-on-vrtx-stock\">\u003Cstrong>Le point de vue de Wall Street sur l'action VRTX\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>Le résultat intermédiaire confirmé de l'essai RAINIER pour le traitement de l'IgAN chez les patients atteints d'insuffisance rénale au premier semestre détermine directement si la direction complète sa demande de BLA et débloque une franchise rénale dont les analystes s'attendent à ce qu'elle rivalise avec celle de CF en termes d'échelle.\u003C\u002Fp>\n\n\n\n\u003Cp>L'argumentaire fondamental tient la route : les revenus passent de 12 milliards de dollars en 2025 à une estimation de 13 milliards de dollars en 2026, tandis que le BPA normalisé grimpe de 18,40 à 19,17 dollars, soutenant une entreprise dont les revenus ont été composés à 14,1 % par an sur cinq ans.\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"830\" height=\"566\" data-public-id=\"images\u002Fimage-69_956817342d\u002Fimage-69_956817342d.png\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_830,h_566,c_scale\u002Ff_webp,q_auto\u002Fv1772598929\u002Fimages\u002Fimage-69_956817342d\u002Fimage-69_956817342d.png?_i=AA\" alt=\"vertex pharmaceuticals stock\" class=\"wp-post-95679 wp-image-95681\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1772598929\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1772598929\u002Fimages\u002Fimage-69_956817342d\u002Fimage-69_956817342d.png?_i=AA 830w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_205,c_scale\u002Ff_webp,q_auto\u002Fv1772598929\u002Fimages\u002Fimage-69_956817342d\u002Fimage-69_956817342d.png?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_524,c_scale\u002Ff_webp,q_auto\u002Fv1772598929\u002Fimages\u002Fimage-69_956817342d\u002Fimage-69_956817342d.png?_i=AA 768w\" sizes=\"auto, (max-width: 830px) 100vw, 830px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Cible des analystes de la rue pour l'action VRTX \u003Cstrong>(\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>TIKR\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>)\u003C\u002Fstrong>\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>En date du 3 mars, Wall Street compte 21 achats, 4 surperformances, 5 conservations et 1 vente, avec un objectif de prix moyen de 535,56 $, ce qui représente une hausse de 12,9 % par rapport à 474,27 $, reflétant le fait que les analystes renforcent leur conviction dans le cadre d'un repli post-résultats plutôt que d'estomper l'histoire.\u003C\u002Fp>\n\n\n\n\u003Cp>La fourchette d'objectifs des analystes s'étend de 330 $ à 625 $, la plus basse supposant que les résultats de pove soient décevants et que la normalisation du rapport brut-net de JOURNAVX s'arrête, tandis que la plus haute suppose que l'intérim de RAINIER soit parfait et que les prescriptions de JOURNAVX triplent, comme la direction l'a prévu pour 2026.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-what-does-the-valuation-model-say\">\u003Cstrong>Que dit le modèle d'évaluation ?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cfigure class=\"wp-block-image size-large\">\u003Cimg width=\"1024\" height=\"832\" data-public-id=\"images\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_832,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA\" alt=\"vertex pharmaceuticals stock\" class=\"wp-post-95679 wp-image-95682\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1772598960\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1024,h_832,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 1024w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_244,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_624,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 768w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1248,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1663,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 2048w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1200,h_975,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 1200w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_1137,c_scale\u002Ff_webp,q_auto\u002Fv1772598960\u002Fimages\u002FVRTX_valuation_model_9568228f3d\u002FVRTX_valuation_model_9568228f3d.webp?_i=AA 1400w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Résultats du modèle d'évaluation des actions VRTX \u003Cstrong>(\u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=21127&tid=2621295&ref=tikrblog\">\u003Cstrong>TIKR\u003C\u002Fstrong>\u003C\u002Fa>\u003Cstrong>)\u003C\u002Fstrong>\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp>Le modèle d'évaluation évalue VRTX à 815,40 $ d'ici décembre 2030, ce qui implique un rendement total de 71,9 % et un TRI annualisé de 11,9 % par rapport aux niveaux actuels, un écart que le marché n'a pas encore comblé malgré cinq années consécutives de croissance à deux chiffres du chiffre d'affaires.\u003C\u002Fp>\n\n\n\n\u003Cp>Quoi qu'il en soit, le marché considère VRTX comme une entreprise de FC en pleine maturité, alors que les revenus non liés à la FC atteignent 500 millions de dollars ou plus rien qu'en 2026. Les marges de revenu net normalisées augmentent pour atteindre 42,5 % à mi-parcours jusqu'en 2031, ce qui réduit le risque perçu de concentration des FC. Les 74 engagements de la direction envers les payeurs, couvrant 210 millions de vies, indiquent une infrastructure commerciale déjà construite avant l'approbation de pove, et non après.\u003C\u002Fp>\n\n\n\n\u003Cp>Les données intermédiaires de RAINIER, qui arriveront au premier semestre, représentent l'événement unique le plus susceptible d'entraîner une réévaluation du sentiment de \" titulaire de FC \" à \" compoundateur multi-franchise \".\u003C\u002Fp>\n\n\n\n\u003Cp>La thèse s'effondre si les données intermédiaires de RAINIER de pove n'atteignent pas la réduction de 47% de l'UPCR attendue par les investisseurs, ce qui bloque la BLA et élimine l'argument de la croissance rénale qui justifie l'objectif moyen de $535,56.\u003C\u002Fp>\n\n\n\n\u003Cp>L'analyse intermédiaire de pove sur IgAN, confirmée pour le premier semestre, validera ou réinitialisera l'ensemble de la thèse de la franchise rénale qui sous-tend l'objectif modèle de 815,40 $.\u003C\u002Fp>\n\n\n\n\u003Cp>Par conséquent, l'action VRTX semble sous-évaluée à 474,27 $, avec un rendement total de 71,9 % selon le modèle et un catalyseur binaire au premier semestre qui pourrait combler l'écart rapidement.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Les meilleures idées de Wall Street ne restent pas cachées longtemps. Surveillez les mises à jour des analystes, les résultats supérieurs aux attentes et les surprises en matière de revenus pour des milliers d'actions dès qu'elles se produisent grâce à TIKR gratuitement →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-should-you-invest-in-vertex-pharmaceuticals-incorporated\">\u003Cstrong>Devriez-vous investir dans Vertex Pharmaceuticals Incorporated ?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>La seule façon de le savoir est d'examiner les chiffres vous-même. TIKR vous donne un accès gratuit aux mêmes données financières de qualité institutionnelle que celles utilisées par les analystes professionnels pour répondre à cette question.\u003C\u002Fp>\n\n\n\n\u003Cp>En consultant l'action VRTX, vous verrez des années de données financières historiques, les prévisions des analystes de Wall Street en matière de revenus et de bénéfices pour les trimestres à venir, l'évolution des multiples d'évaluation au fil du temps et la tendance à la hausse ou à la baisse des objectifs de prix.\u003C\u002Fp>\n\n\n\n\u003Cp>Vous pouvez créer une liste de surveillance gratuite pour suivre Vertex Pharmaceuticals Incorporated en même temps que toutes les autres actions qui vous intéressent. Aucune carte de crédit n'est requise. Juste les données dont vous avez besoin pour décider par vous-même.\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>Accédez gratuitement à des outils professionnels pour analyser l'action VRTX sur TIKR →\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003C\u002Fp>\n",820,"fr","\u002Fblog\u002Fvertex-pharmaceuticals-why-a-815-target-makes-its-current-price-look-undervalued","vertex-pharmaceuticals-why-a-815-target-makes-its-current-price-look-undervalued","images\u002FFEATURED-IMAGE-MAKER-397\u002FFEATURED-IMAGE-MAKER-397","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772599035\u002Fimages\u002FFEATURED-IMAGE-MAKER-397\u002FFEATURED-IMAGE-MAKER-397.png?_i=AA",{"altText":237,"imageCredit":238},"Vertex Pharmaceuticals Posted $12 Billion in Revenue Last Year: Analysts Point to a $815 Stock Price","TIKR",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Gian Estrada","giantikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"Thomas Richmond","thomastikr","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"Examens des Actions","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"Vertex posted $12 billion in 2025 revenue and guided for $13.1 billion in 2026, but the number that matters most arrives in H1 when pove’s pivotal IgAN trial readout either unlocks or resets a franchise analysts say could rival CF entirely.",{"title":237,"description":260,"twitterTitle":237,"twitterDescription":260,"author":240,"articlePublisher":261,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":262,"twitterData1":263,"ogTitle":237,"ogDescription":260,"ogUrl":232,"ogImage":235,"ogImageWidth":264,"ogImageHeight":265,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"Vertex posted $12 billion in 2025 revenue and guided for $13.1 billion in 2026, but the number that matters most arrives in H1 when pove’s pivotal IgAN trial readout either unlocks or resets a franchise analysts say could rival CF entirely.","TIKR.com","Temps de lecture estimé","7 minutes",1200,630,[267,281,298,313,329],{"id":255,"title":268,"date":269,"excerpt":270,"wordCount":271,"uri":272,"slug":273,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":274,"featuredImageMetadata":275,"author":276,"categories":278,"relatedPosts":280},"Pourquoi l'action Boston Scientific pourrait rapporter 70 % bien qu'elle se négocie près de son plus bas niveau de la semaine 52","2026-03-04 13:40:59","Wall Street a passé des mois à considérer Boston Scientific comme une pure histoire d'EP et de WATCHMAN, mais un accord de 6 milliards de dollars avec Penumbra, une croissance de 38 % du flux de trésorerie disponible et 25 évaluations d'achat en disent tout autrement.",802,"\u002Fblog\u002Fwhy-boston-scientific-stock-could-return-70-despite-trading-near-its-52-week-low","why-boston-scientific-stock-could-return-70-despite-trading-near-its-52-week-low","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F03\u002FFEATURED-IMAGE-MAKER-394-600x360.png",{"altText":268},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":277},[],[279],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":282,"date":283,"excerpt":284,"wordCount":285,"uri":286,"slug":287,"cloudinaryAssetId":288,"featuredImageOriginalUrl":289,"featuredImageMetadata":290,"author":291,"categories":295,"relatedPosts":297},"Texas Instruments est en hausse de 17 % depuis le début de l'année. Voici où l'action pourrait aller en 2026","2026-03-04 13:35:00","L'action Texas Instruments est en hausse d'environ 17 % depuis le début de l'année, grâce à l'amélioration de la demande de semi-conducteurs et à une forte génération de liquidités. Voici pourquoi la croissance des marchés de l'industrie, de l'automobile et des centres de données pourrait contribuer à faire progresser l'action en 2026.",654,"\u002Fblog\u002Ftexas-instruments-is-up-17-year-to-date-heres-where-the-stock-could-go-in-2026","texas-instruments-is-up-17-year-to-date-heres-where-the-stock-could-go-in-2026","images\u002F@Corina-Ciocirlans-Images-via-Canva-1\u002F@Corina-Ciocirlans-Images-via-Canva-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772616047\u002Fimages\u002F@Corina-Ciocirlans-Images-via-Canva-1\u002F@Corina-Ciocirlans-Images-via-Canva-1.png?_i=AA",{"altText":282},{"name":292,"slug":293,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":294},"Nikko Henson","nikkotikr",[],[296],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":299,"date":300,"excerpt":301,"wordCount":302,"uri":303,"slug":304,"cloudinaryAssetId":305,"featuredImageOriginalUrl":306,"featuredImageMetadata":307,"author":308,"categories":310,"relatedPosts":312},"Alphabet a perdu 11 % au cours des 30 derniers jours. Voici où l'action pourrait aller en 2026","2026-03-04 13:05:00","L'action Alphabet a perdu environ 11 % au cours des 30 derniers jours, les investisseurs évaluant le coût à court terme de la mise à l'échelle de l'infrastructure d'IA par rapport à la forte demande de services de cloud et d'IA générative. Voici pourquoi l'écosystème d'IA en expansion d'Alphabet et l'élan du cloud pourraient encore soutenir une hausse significative jusqu'en 2026.",738,"\u002Fblog\u002Falphabet-is-down-11-in-the-last-30-days-heres-where-the-stock-could-go-in-2026","alphabet-is-down-11-in-the-last-30-days-heres-where-the-stock-could-go-in-2026","images\u002F@deepanker70-from-pixabay-via-Canva-123\u002F@deepanker70-from-pixabay-via-Canva-123","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772614861\u002Fimages\u002F@deepanker70-from-pixabay-via-Canva-123\u002F@deepanker70-from-pixabay-via-Canva-123.png?_i=AA",{"altText":299},{"name":292,"slug":293,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":309},[],[311],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":314,"date":315,"excerpt":316,"wordCount":317,"uri":318,"slug":319,"cloudinaryAssetId":320,"featuredImageOriginalUrl":321,"featuredImageMetadata":322,"author":324,"categories":326,"relatedPosts":328},"Pourquoi l'action Johnson & Johnson a progressé de 50 % l'an dernier et pourrait atteindre de nouveaux sommets en 2026","2026-03-04 13:00:00","L'activité de médecine innovante de J&J a progressé de près de 15 % en 2025, hors STELARA, mais l'objectif moyen de Wall Street de 233,13 $ est inférieur au prix actuel, ce qui suggère que les analystes sous-évaluent le prochain cycle de croissance de l'entreprise.",848,"\u002Fblog\u002Fwhy-johnson-johnson-stock-rose-50-last-year-and-could-set-new-highs-in-2026","why-johnson-johnson-stock-rose-50-last-year-and-could-set-new-highs-in-2026","images\u002FFEATURED-IMAGE-MAKER-398\u002FFEATURED-IMAGE-MAKER-398","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_360,c_scale\u002Ff_webp,q_auto\u002Fv1772600097\u002Fimages\u002FFEATURED-IMAGE-MAKER-398\u002FFEATURED-IMAGE-MAKER-398.png?_i=AA",{"altText":323},"Pourquoi l'action Johnson & Johnson a progressé de 50 % l'an dernier et pourrait atteindre de nouveaux sommets en 2026",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":325},[],[327],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":330,"date":331,"excerpt":332,"wordCount":333,"uri":334,"slug":335,"cloudinaryAssetId":336,"featuredImageOriginalUrl":337,"featuredImageMetadata":338,"author":339,"categories":341,"relatedPosts":343},"DoorDash a augmenté de 7% cette semaine. Voici à combien pourrait s'élever l'action d'ici 2028","2026-03-04 12:35:00","L'action DoorDash a augmenté d'environ 7 % cette semaine, les investisseurs ayant réagi à la publication de résultats solides et à l'intérêt continu des investisseurs institutionnels pour la société. Voici pourquoi l'expansion du réseau de livraison de DoorDash et l'amélioration de l'économie de marché pourraient favoriser une hausse à long terme.",698,"\u002Fblog\u002Fdoordash-rose-7-this-week-heres-how-much-the-stock-could-rise-by-2028","doordash-rose-7-this-week-heres-how-much-the-stock-could-rise-by-2028","images\u002F@Pop-Andreeas-Images-via-Canva\u002F@Pop-Andreeas-Images-via-Canva","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772613140\u002Fimages\u002F@Pop-Andreeas-Images-via-Canva\u002F@Pop-Andreeas-Images-via-Canva.png?_i=AA",{"altText":330},{"name":292,"slug":293,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":340},[],[342],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[345,365,380,399,414,429,446,458,473,487],{"id":255,"title":346,"date":347,"excerpt":348,"wordCount":349,"uri":350,"slug":351,"cloudinaryAssetId":352,"featuredImageOriginalUrl":353,"featuredImageMetadata":354,"author":355,"categories":359,"relatedPosts":364},"L'action Best Buy bondit de 7 %, l'amélioration de la rentabilité compensant la baisse du chiffre d'affaires","2026-03-04 13:58:00","L'action Best Buy progresse de 4 %, la hausse des bénéfices compensant la baisse du chiffre d'affaires. L'amélioration de la rentabilité et les nouvelles initiatives de croissance enthousiasment les investisseurs malgré la faiblesse de la demande.",665,"\u002Fblog\u002Fbest-buy-nyse-stock-jump-7-as-improved-profitability-offsets-revenue-decline","best-buy-nyse-stock-jump-7-as-improved-profitability-offsets-revenue-decline","images\u002FBBY-stock\u002FBBY-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772621503\u002Fimages\u002FBBY-stock\u002FBBY-stock.png?_i=AA",{"altText":346},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":358},"Aditya Raghunath","adityatikr",[],[360],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},"Mises à Jour des Résultats","earnings-updates","\u002Fblog\u002Fcategory\u002Fearnings-updates",[],{"id":255,"title":366,"date":367,"excerpt":368,"wordCount":369,"uri":370,"slug":371,"cloudinaryAssetId":372,"featuredImageOriginalUrl":373,"featuredImageMetadata":374,"author":375,"categories":377,"relatedPosts":379},"Pourquoi l'action d'AeroVironment a chuté de plus de 20 % cette semaine","2026-03-04 10:55:00","AeroVironment plonge de 19 % après que l'armée de l'espace a rouvert l'appel d'offres pour un contrat SCAR de 1,4 milliard de dollars. Raymond James rétrograde l'action de \"strong buy\" à \"underperform\".",799,"\u002Fblog\u002Fwhy-aerovironment-avav-stock-tanked-over-20-this-week","why-aerovironment-avav-stock-tanked-over-20-this-week","images\u002FAVAV-stock_955099f985\u002FAVAV-stock_955099f985","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772536085\u002Fimages\u002FAVAV-stock_955099f985\u002FAVAV-stock_955099f985.png?_i=AA",{"altText":366},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":376},[],[378],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},[],{"id":255,"title":381,"date":382,"excerpt":383,"wordCount":384,"uri":385,"slug":386,"cloudinaryAssetId":387,"featuredImageOriginalUrl":388,"featuredImageMetadata":389,"author":391,"categories":393,"relatedPosts":398},"L'action Albemarle est en tête des pertes du S&P 500, le producteur de lithium chutant de 8 %.","2026-03-04 10:58:00","Les actions d'Albemarle chutent de 8 % en raison de la chute de 13 % des prix du lithium en Chine. La faiblesse des ventes de VE de BYD et les tensions au Moyen-Orient assombrissent les perspectives de la demande pour le producteur.",596,"\u002Fblog\u002Falbemarle-nyse-stock-leads-sp-500-losses-as-lithium-producer-sinks-8","albemarle-nyse-stock-leads-sp-500-losses-as-lithium-producer-sinks-8","images\u002FALB-stock\u002FALB-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772620530\u002Fimages\u002FALB-stock\u002FALB-stock.png?_i=AA",{"altText":390},"L'action Albemarle est en tête des pertes du S&P 500, le producteur de lithium chutant de 8 %.",{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":392},[],[394],{"name":395,"slug":396,"uri":397,"description":243,"postsCount":255},"Investissement Général","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",[],{"id":255,"title":400,"date":401,"excerpt":402,"wordCount":403,"uri":404,"slug":405,"cloudinaryAssetId":406,"featuredImageOriginalUrl":407,"featuredImageMetadata":408,"author":409,"categories":411,"relatedPosts":413},"Barclays ramène la note de l'action Blue Owl à \"Equal Weight\" alors que la chute du cours de l'action se poursuit","2026-03-03 11:59:00","Barclays abaisse la note de Blue Owl Capital en raison d'un fort ralentissement des entrées de capitaux dans les BDC non cotées et d'une forte augmentation des rachats. L'action a baissé de 50 % au cours de l'année écoulée en raison des craintes liées au crédit.",775,"\u002Fblog\u002Fbarclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","barclays-cuts-blue-owl-nyse-owl-stock-rating-equal-weight-price-plunge","images\u002FOWL-stock-1\u002FOWL-stock-1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772533744\u002Fimages\u002FOWL-stock-1\u002FOWL-stock-1.png?_i=AA",{"altText":400},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":410},[],[412],{"name":395,"slug":396,"uri":397,"description":243,"postsCount":255},[],{"id":255,"title":415,"date":416,"excerpt":417,"wordCount":418,"uri":419,"slug":420,"cloudinaryAssetId":421,"featuredImageOriginalUrl":422,"featuredImageMetadata":423,"author":424,"categories":426,"relatedPosts":428},"L'action Novo Nordisk atteint son plus bas niveau en 52 semaines, Goldman Sachs la rétrograde à \"neutre\".","2026-03-03 10:55:00","L'action Block a augmenté de plus de 20 % après que la société fintech a annoncé qu'elle allait licencier plus de 4 000 employés, soit environ la moitié de ses effectifs.",655,"\u002Fblog\u002Fnovo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","novo-nordisk-nyse-nvo-stock-hits-52-week-low-as-goldman-sachs-downgrades-it-to-neutral","images\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772532602\u002Fimages\u002FNVO-stock_954941bea1\u002FNVO-stock_954941bea1.png?_i=AA",{"altText":415},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":425},[],[427],{"name":395,"slug":396,"uri":397,"description":243,"postsCount":255},[],{"id":255,"title":430,"date":367,"excerpt":431,"wordCount":432,"uri":433,"slug":434,"cloudinaryAssetId":435,"featuredImageOriginalUrl":436,"featuredImageMetadata":437,"author":438,"categories":440,"relatedPosts":445},"En baisse de 9 % par rapport à son plus haut niveau historique, l'action Stryker peut-elle offrir de nouveaux rendements en 2026 ?","La forte dynamique du Mako et la croissance robuste du MedSurg sont à l'origine des perspectives de Stryker. L'action pourrait atteindre 503 $ d'ici 2028, ce qui représente une hausse de 30 % par rapport aux niveaux actuels.",1262,"\u002Fblog\u002Fdown-9-from-all-time-high-can-stryker-nyse-stock-deliver-further-returns-in-2026","down-9-from-all-time-high-can-stryker-nyse-stock-deliver-further-returns-in-2026","images\u002FSYK-stock\u002FSYK-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772517855\u002Fimages\u002FSYK-stock\u002FSYK-stock.png?_i=AA",{"altText":430},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":439},[],[441],{"name":442,"slug":443,"uri":444,"description":243,"postsCount":255},"Évaluation","valuation","\u002Fblog\u002Fcategory\u002Fvaluation",[],{"id":255,"title":447,"date":367,"excerpt":448,"wordCount":432,"uri":449,"slug":450,"cloudinaryAssetId":-1,"featuredImageOriginalUrl":451,"featuredImageMetadata":452,"author":453,"categories":455,"relatedPosts":457},"En hausse de 54 % au cours des 12 derniers mois, l'action Analog Devices peut-elle continuer sur sa lancée en 2026 ?","L'action d'Analog Devices a bondi de 56 % en 12 mois grâce à la demande d'infrastructures d'IA. Cette dynamique peut-elle se poursuivre ? Nous analysons l'objectif de cours de 422 $ d'ADI et son potentiel de hausse de 20 %.","\u002Fblog\u002Fup-56-in-last-12-months-can-analog-devices-nyse-adi-stock-continue-its-strong-run-in-2026","up-56-in-last-12-months-can-analog-devices-nyse-adi-stock-continue-its-strong-run-in-2026","https:\u002F\u002Ftikr1.wpengine.com\u002Fwp-content\u002Fuploads\u002F2026\u002F03\u002FADI-stock-600x400.png",{"altText":447},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":454},[],[456],{"name":442,"slug":443,"uri":444,"description":243,"postsCount":255},[],{"id":255,"title":459,"date":460,"excerpt":461,"wordCount":462,"uri":463,"slug":464,"cloudinaryAssetId":465,"featuredImageOriginalUrl":466,"featuredImageMetadata":467,"author":468,"categories":470,"relatedPosts":472},"En baisse de 25 % par rapport à son plus haut niveau historique, l'action Capital One peut-elle offrir de meilleurs rendements en 2026 ?","2026-03-03 11:25:00","L'action Capital One pourrait générer des rendements de 30 % d'ici 2028, l'intégration de Discover et l'acquisition de Brex débloquant la croissance du réseau de paiements et l'expansion des services bancaires aux entreprises.",1309,"\u002Fblog\u002Fdown-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","down-25-from-all-time-high-can-capital-one-nyse-stock-deliver-better-returns-in-2026","images\u002FCOF-stock\u002FCOF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772516734\u002Fimages\u002FCOF-stock\u002FCOF-stock.png?_i=AA",{"altText":459},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":469},[],[471],{"name":442,"slug":443,"uri":444,"description":243,"postsCount":255},[],{"id":255,"title":474,"date":416,"excerpt":475,"wordCount":476,"uri":477,"slug":478,"cloudinaryAssetId":479,"featuredImageOriginalUrl":480,"featuredImageMetadata":481,"author":482,"categories":484,"relatedPosts":486},"En hausse de 20 % au cours des 12 derniers mois, l'action Synchrony Financial peut-elle évoluer à la hausse en 2026 ?","En hausse de 20% sur 12 mois, Synchrony Financial est prometteur avec la croissance du partenariat avec Walmart. Notre modèle prévoit une hausse de 27% à 87 $ d'ici décembre 2028. Analyse à l'intérieur.",1261,"\u002Fblog\u002Fup-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","up-20-in-last-12-months-can-synchrony-financial-syf-stock-deliver-further-in-2026","images\u002FSYF-stock\u002FSYF-stock","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772512295\u002Fimages\u002FSYF-stock\u002FSYF-stock.png?_i=AA",{"altText":474},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":483},[],[485],{"name":442,"slug":443,"uri":444,"description":243,"postsCount":255},[],{"id":255,"title":488,"date":489,"excerpt":490,"wordCount":491,"uri":492,"slug":493,"cloudinaryAssetId":494,"featuredImageOriginalUrl":495,"featuredImageMetadata":496,"author":497,"categories":499,"relatedPosts":501},"En hausse de 42 % en 3 ans, l'action de Raymond James Financial peut-elle continuer à progresser ?","2026-03-03 09:55:00","L'action Raymond James a baissé de 10 % en 12 mois. Un fort recrutement, 31 milliards de dollars de nouveaux actifs nets signalent une reprise. Notre modèle prévoit une hausse de 21 % pour atteindre 185 $ d'ici septembre 2028.",1234,"\u002Fblog\u002Fup-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","up-42-in-3-years-can-raymond-james-financial-nyse-rjf-stock-deliver-further","images\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1772467602\u002Fimages\u002FRJF-stock_9542509878\u002FRJF-stock_9542509878.png?_i=AA",{"altText":488},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":498},[],[500],{"name":442,"slug":443,"uri":444,"description":243,"postsCount":255},[]]